HEPION PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
HEPION PHARMACEUTICALS, INC. (HEPA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $467.60 per share for the 12-month period ending 2019-12-31, per its 10-K filed 2020-05-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2020-05-14
- HEPION PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2019 was $467.60, a 4853.39% increase from fiscal 2018.
- HEPION PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2018 was $9.44.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|
| 2019-12-31 | $467.60 10-K · filed 2020-05-14 | |
| 2018-12-31 | $9.44 10-K · filed 2020-05-14 | |
| 2018-09-30 | $13.63 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |